Physician profile
Aurora Dogaru
NPI 1013948744
$22,339.34
in general payments reported to CMS, 2019-2025
22 companies · $5,001 in 2025
The $5,001 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,537 · 2020: $1,120 · 2021: $1,868 · 2022: $2,812 · 2023: $3,478 · 2024: $3,524 · 2025: $5,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,931.80 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $4,316.84 | 2019-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $3,565.61 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $2,181.82 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $2,013.52 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $1,392.22 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,351.34 | 2022-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,186.84 | 2019-2025 | |
| Allergan, INC. | $1,080.16 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $1,063.14 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $950.41 | 2019-2025 | Kisunla |
| Sunovion Pharmaceuticals INC. | $888.93 | 2019-2020 | |
| Alkermes, INC. | $807.34 | 2021-2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $357.63 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $299.59 | 2019 | |
| Avanir Pharmaceuticals, INC. | $126.08 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Airsupra |
| Novo Nordisk INC | $125.00 | 2024 | Wegovy |
| Grifols USA, LLC | $125.00 | 2025 | Hyperrab |
| Jazz Pharmaceuticals INC. | $125.00 | 2020 | |
| Idorsia Pharmaceuticals US INC | $122.91 | 2023 | Quviviq |
| Qol Medical, LLC | $84.39 | 2023 | Sucraid |
| Alfasigma USA, INC. | $50.57 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Dogaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.